A Novel Peptide Derived from Human Pancreatitis-Associated Protein Inhibits Inflammation In Vivo and In Vitro and Blocks NF-Kappa B Signaling Pathway by Yang, Xiaolu et al.
A Novel Peptide Derived from Human Pancreatitis-
Associated Protein Inhibits Inflammation In Vivo and In
Vitro and Blocks NF-Kappa B Signaling Pathway
Xiaolu Yang
1,2, Huiyi Jin
1,2, Kun Liu
1,2, Qing Gu
1,2, Xun Xu
1,2*
1Department of Ophthalmology, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China, 2Shanghai Key Laboratory of
Fundus Disease, Shanghai, People’s Republic of China
Abstract
Background: Pancreatitis-associated protein (PAP) is a pancreatic secretory protein belongs to the group VII of C-type lectin
family. Emerging evidence suggests that PAP plays a protective effect in inflammatory diseases. In the present study, we
newly identified a 16-amino-acid peptide (named PAPep) derived from C-type lectin-like domain (CTLD) of human PAP with
potent anti-inflammatory activity using both in vivo and in vitro assays.
Methodology/Principal Findings: We assessed the anti-inflammatory effect of PAPep on endotoxin-induced uveitis (EIU) in
rats and demonstrated that intravitreal pretreatment of PAPep concentration-dependently attenuated clinical manifestation
of EIU rats, reduced protein leakage and cell infiltration into the aqueous humor (AqH), suppressed tumor necrosis factor
(TNF)-a, interleukin (IL)-6, intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein (MCP)-1
production in ocular tissues, and improved histopathologic manifestation of EIU. Furthermore, PAPep suppressed the LPS-
induced mRNA expression of TNF-a and IL-6 in RAW 264.7 cells, inhibited protein expression of ICAM-1 in TNF-a-stimulated
human umbilical vein endothelial cells (HUVECs) as well as U937 cells adhesion to HUVECs. Western blot analysis in ocular
tissues and different cell lines revealed that the possible mechanism for this anti-inflammatory effect of PAPep may depend
on its ability to inhibit the activation of NF-kB signaling pathway.
Conclusions/Significance: Our studies provide the first evidence that the sequence of PAPep is within the critically active
region for the anti-inflammatory function of PAP and the peptide may be a promising candidate for the management of
ocular inflammatory diseases.
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Introduction
Uveitis is a relatively common intraocular inflammatory disease
and one of the most damaging ocular conditions that its recurrent
nature could lead to cataract, macular edema, glaucoma, and,
ultimately, destruction of the intraocular tissues and blindness [1].
Although age-related macular degeneration, glaucoma, and
diabetic retinopathy are more prevalent causes of blindness, the
relative youth of patients diagnosed with uveitis makes it inevitably
one of the ocular diseases with an important socioeconomic impact
[2].
Present pharmacological treatment for uveitis primarily includes
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids
and immunosuppressive agents such as cyclosporin A [3].
However, these drugs do not completely control the disease in
many patients and long term application of these drugs may result
in multiple adverse effects such as cataract, glaucoma, suscepti-
bility to microbial infection and nephrotoxicity [4–7]. Hence,
there is a need for therapeutics with safer modes of action. Small
peptides are emerging and promising agents in developing new
therapeutics for different diseases. The advantages of some
peptides as drugs over proteins include sufficient penetration
capability, potential efficacy, less toxicity, lower immunogenicity
and controllable production, which make them potential alterna-
tives for ocular application. Thus, researchers began to show
interests in the active fragments of large proteins that target
inflammation [8–11].
Pancreatitis-associated protein (PAP) is a 16.6 kDa pancreatic
secretory protein belongs to the group VII of C-type lectin family.
It is comprised of a short N-terminal domain and a large C-type
lectin-like domain (CTLD) that spans the rest of the protein [12–
15]. Emerging evidence supports the notion that PAP plays a
protective effect against inflammatory damage in pancreatic
[16,17] and extrapancreatic [18,19] inflammatory conditions,
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pancreatitis, the infusion of anti-PAP1 antibodies worsened the
pancreatic inflammatory response and PAP1 treatment prevented
tumor necrosis factor (TNF)-a-induced Nuclear Factor kappa B
(NF–kB) activation in macrophages [16]. In addition, PAP
prevented fMLP-induced vasoconstriction and edema formation
in the isolated rabbit lung and protected the lung from neutrophil-
induced injury [18]. Studies by Gironella et al. [19] found that
PAP is anti-inflammatory in patients with inflammatory bowel
disease. It was also reported that PAP inhibited macrophage
activation by down-regulating the synthesis of TNF-a and
interleukin (IL)-6, thereby promoting an anti-inflammatory state
[20], which are possibly mediated through the inhibition of NF-kB
pathway [21–23].
In the present study, we chose three conserved sequence
segments from CTLD of human PAP to construct three small
peptides. We used bioinformatics methods to evaluate their
biological activities and investigated these peptides’ effects on
ocular inflammation, using an established animal model, endo-
toxin-induced uveitis (EIU), and finally focused on one of these
three peptides with the sequence of ASLSRSTAFLRWKDYN
(named PAPep). We found that PAPep peptide diminished the
inflammatory reaction in EIU rats, suppressed the LPS-induced
cytokine release in ocular tissues and macrophage RAW 264.7
cells, and inhibit adhesion molecule expression in stimulated
endothelial cells. In order to gain a further mechanistic insight, we
assessed whether PAPep modulates activation of NF-kB in ocular
tissues and two different cell lines, namely, RAW264.7 cells and
HUVECs, as models of the cell types that orchestrate the
inflammation present in uveitis. These interesting results suggest
that PAPep peptide is within the key active region of PAP CTLD
and a potential anti-inflammatory therapeutic agent.
Materials and Methods
Ethics Statement
All studies involving animals were conducted in strict accor-
dance with the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic
and Vision Research. The protocol was approved by the Ethics
Committee of Shanghai First People’s Hospital, Shanghai Jiaotong
University, Shanghai, China (Permit Number: 2009–0086). All
surgeries were performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Peptide Identification and Synthesis
In order to identify the sequence segment that is most probably
within the critically active region from CTLD of human PAP, we
first did comparative alignment of the amino acid sequence of
human PAP with mouse, rat, dog and sheep PAP isoforms using
the ClustalW program and chose regions with higher homology
amongst various species. Second, we investigated the second
structure of PAP and found out that there are several helical and
beta-strand regions within the protein sequence (Figure 1). It is
reported that helical conformation is a feature of some
antibacterial peptides [24–27]. So we selected sequence regions
with helical conformation. Based on the results of the combined
analysis, we ultimately chose three sequence segments derived
from the CTLD of human PAP to synthesize three peptides 16
amino acids in length (P1: YALFLSPKSWTDADLA, P2:
VLSGAEGSFVSSLVKS, P3: ASLSRSTAFLRWKDYN, P3
named PAPep here). Prior to synthesis, the biological activity of
the three peptides were analyzed using bioinformatics methods
[28,29], which include physicochemical parameters, analysis of
antigenicity, surface accessibility and mean hydrophilicity.
The three peptides was synthesized and purified by ChinaPep-
tides Co., Ltd. in Shanghai, PR China with a high-efficiency solid-
phase method using an automatic peptide synthesizer (Symphony;
Protein Technologies, Tucson, AZ). These purified peptides were
characterized by means of amino acid analysis, high-performance
liquid chromatography (HPLC, analytical; Shimadzu, Kyoto,
Japan) and mass spectrometry (MS, Finnigan TSQ 7000; Thermo,
Waltham, MA) with the purity more than 95%. In order to
identify whether the PAPep function of anti-inflammation is
sequence-dependent, a scrambled peptide (PAPS) was simulta-
neously synthesized and used as a negative control for the
following in vivo and in vitro experiments. Synthetic peptides were
reconstituted in phosphate-buffered saline (PBS; pH7.4) for the
experiments.
Induction of EIU and Drug Treatment Protocol
Six- to eight-week-old Wistar rats (160–180 g) were obtained
from Shanghai Laboratory Animal Center, Chinese Academy of
Sciences. Animals were maintained in a 12 h light/12 h dark
cycle. Food and water were supplied ad libitum. EIU was induced
by a single footpad injection of 100 ml sterile pyrogen free saline
containing 200 mg lipopolysaccharide (LPS) from Escherichia coli
(Sigma-Aldrich, Inc., St. Louis, MO). A separate group received
the same volume of sterilized saline in one foot pad for comparison
Figure 1. Amino acid sequence of human PAP. The secondary structure is depicted above the primary sequence. Red arrows above the
sequences correspond to helical regions. Blue arrows above the sequences correspond to beta-strand regions. Signal sequence is indicated
underlined. The blue boxed region corresponds to the N-terminal PAP domain. The C-type lectin domain is indicated in italic. The yellow boxed
region is the C-type lectin consensus sequence. Cysteines involved in the formation of the three disulfide bonds are highlighted in red. Three distinct
regions from which peptides are processed out are boxed in red as follows: P1, PAP[52–67]; P2, PAP[79–94]; P3 (PAPep), PAP[147–162].
doi:10.1371/journal.pone.0029155.g001
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anesthetized and pupils were dilated before experimental manip-
ulations. Different concentration peptides (P1–P3 and PAPS) were
injected intravitreally to both rat eyes, using a pump microinjec-
tion apparatus under a dissecting microscope, an hour before LPS
was administered, as previously described [30]. LPS group also
received intravitreal injection of PBS (vehicle) in a comparable
volume at the same time points as the peptides. Dexamethasone
sodium phosphate (10 mg/injection; Shanghai General Motors
Pharmaceutical Industry Company Limited, China) was used as a
positive control for anti-inflammatory activity on EIU. Twenty-
four hours after LPS injection, rats were killed and processed for
clinical, biological and immunohistochemical analysis. Five
normal rats were injected intravitreally with PAPep (10 mg/eye)
to detect any proinflammatory effect in the eye and examined with
a slit-lamp biomicroscope for 3 days to determine the short-term
safety of the treatment. The experiments were repeated at least
three times to ensure reproducibility.
Clinical Scoring
Animals were examined with a biomicroscope 24 h after LPS
injection. Clinical manifestations of EIU were graded from 0 to 4
in a blinded fashion according to the previously reported scoring
system [31]: 0=no inflammatory reaction; 1=discrete dilation of
iris and conjunctival vessels; 2=moderate dilation of iris and
conjunctival vessels with moderate flare in the anterior chamber;
3=intense iridal hyperemia with intense flare in the anterior
chamber; 4=same clinical signs as 3 with presence of fibrinoid
exudation in the pupillary area and miosis. No signs of uveitis were
observed in the animals at the beginning of each experiment.
Clinical EIU was considered positive when .1. EIU clinical data
shown were representative of 3 sets of experiments and presented
as mean 6 standard deviation (SD).
Number of Infiltrating Cells and Protein Concentration in
Aqueous Humor
Immediately after the biomicroscope examination, the animals
were killed with an overdose of anesthesia. Aqueous humor (AqH)
was collected immediately from both eyes by an anterior chamber
puncture (30–40 ml/rat), using a 30-gauge needle under a surgical
microscope. For cell counting, the sample was suspended in an
equal amount of Tu ¨rk stain solution, and the cell number was
counted with a hemocytometer under a light microscope. The
number of cells per field was manually counted by two
independent researchers, and the number of cells per microliter
was obtained by averaging the results of four fields from each
sample. Total protein concentration was measured by a
Coomassie Plus (Bradford) Assay Kit (Pierce, Rockford, IL,
USA). The AqH samples were stored in ice water until testing,
and cell counts and total protein concentrations were measured on
the day of sample collection.
Enzyme-Linked-Immunosorbent Assay (ELISA)
The AqH from both eyes of a rat were centrifuged at 2500 rpm
for 20 minutes at 4uC, to obtain the supernatant. Protein levels of
TNF-a, IL-6 in the aqueous humor were determined by the rat
TNF-a and IL-6 ELISA kits (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instruction. The minimum
detectable dose of rat TNF-a and IL-6 is about 5.0 pg/ml and
21.0 pg/ml respectively.Soon after collection of aqueous humor,
both eyes were immediately enucleated. The iris ciliary body (ICB)
and retina complex of each rat was carefully isolated and placed
into 200 ml lysis buffer supplemented with protease inhibitors and
then sonicated. The lysate was centrifuged at 15,000 rpm for 20
minutes at 4uC. The protein levels of intercellular adhesion
molecule-1 (ICAM-1) and monocyte chemoattractant protein
(MCP)-1 in the supernatant were determined with the rat ICAM-1
(R&D Systems, Minneapolis, MN, USA) and MCP-1 (Invitrogen,
Grand Island, NY) ELISA kits, respectively, according to the
manufacturer’s protocols. The minimum detectable dose of rat
ICAM-1 and MCP-1 is about 2.0 pg/ml and 8.0 pg/ml
respectively. All measurements were performed in duplicate. The
data represent the mean of eight assay results 6 SD.
Histopathological Studies
A separate set of rats treated in the same way as described
earlier were used for the histological study. 24 h after LPS
injection, the eyes were enucleated immediately and stored in a
mixture of 10% formalin and 2.5% glutaraldehyde for 24 h. After
dehydration and paraffin embedment of the eyes, five micrometer
sagittal sections near the optic nerve head were obtained. For
histopathological evaluation, tissue sections were deparaffinized
with xylene and stained using hematoxylin and eosin. Infiltrating
inflammatory cells in ICB and posterior vitreous were counted and
identified histologically in a masked fashion by an ocular
pathologist using a counting grid at 4006magnification. The
number of infiltrating inflammatory cells in six sections per eye in
the ICB and in three sections per eye in the posterior vitreous was
averaged and recorded.
Cell Culture
Mouse macrophage-like cell line RAW264.7 (ATCC, Manassas,
VA) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen-Gibco, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS; ScienceCell, San Diego, CA),
100 U/ml penicillin, 100 mg/ml streptomycin at 37uCi na
humidified atmosphere containing 5% CO2. Human umbilical
vein endothelial cells (HUVECs) (ScienCell
TM no.: 8000) and
endothelial cell culture media (ECM) were obtained from
ScienCell Research Laboratories (San Diego, CA, USA). U937
human monocyte-like cell line (ATCC, Manassas, VA) were
maintained in RPMI-1640 containing 1800 mg/l NaHCO3,
4500 mg/l glucose, and 110 mg/l sodium pyruvate, supplemented
with 10% FBS, 100 U/ml penicilin and 100 mg/ml streptomycin
at 37uC in a humidified atmosphere with 5% CO2.
Cell Viability Assay
RAW 264.7 cells and HUVECs were grown in a final volume of
100 ml of culture medium per well in 96-well plates (2610
4 cells/
well) and were serum-starved overnight. To measure cytotoxicity,
cells were treated with various concentrations of peptides (1, 10,
50, 100 mM) and incubated for another 24 h. Cell viability was
measured at the end of treatment by the addition of 20 ml of the 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sul-
phophenyl)-2H-tetrazolium (MTS) reagent for 3 h at 37uC. The
optical density was measured spectrophotometrically at 490 nm
on a microtiter plate reader (Bio-Rad, Model 680, Hercules,
CA). The experiments were repeated three times. Results are
expressed as a percentage of the viability rate, which was
calculated as (optical density of drug treated sample/PBS-
treated control sample) 6100%.
Assessment of PAPep Effects on Stimulated TNF-a and IL-
6 Expression in RAW264.7 Cells
RAW264.7 cells were grown to confluence in 6-well plates and
starved in serum-free DMEM for 12 h before addition of the LPS
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added to the culture medium an hour before LPS stimulation
(100 ng/ml). PAPS (50 mM) and dexamethasone (10 mM) were
also added to the culture medium at the same time points as
PAPep. Spontaneous cytokine production was determined using
the cell culture medium without LPS. After an additional
incubation of 6 h, total RNA was obtained to evaluate changes
in TNF-a and IL-6 mRNA expression using quantitative real time
reverse transcription-polymerase chain reaction (RT-PCR) anal-
ysis on a LightCycler detection system (Roche Applied Science,
Basel, Switzerland).
Total RNA was extracted from cultures with TRIzol Reagent
(Invitrogen, Grand Island, NY) according to the manufacturer’s
protocol. cDNA from each sample was synthesized from 2 mgo f
total RNA using random hexamers and expanded by reverse
transcription with a commercially available kit (RevertAidTM
First Strand cDNA Synthesis Kit, Fermentas). Quantitative real
time PCR was performed with SYBR Premix Ex TaqTM (Takara,
TaKaRa Biotechnology, Dalian, China) according to the manu-
facturer’s protocols. The reaction conditions were 40 cycles of two-
stage PCR consisting of denaturation at 95uC for 30 sec,
annealing at 60uC for 30 sec after an initial denaturation step at
95uC for 5 sec. Expression levels of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) gene were used as an internal control.
Primer and probes used to analyze TNF-a, IL-6, and GAPDH
expression are summarized as follows: for TNF-a: forward primer
59-GACGTGGAACTGGCAGAAGAG-39, reverse primer 59-
TTGGTGGTTTGTGAGTGTGAG-39; for IL-6: forward prim-
er 59-TCTTGGGACTGATGCTGGTG-39, reverse primer 59-
TTGGGAGTGGTATCCTCTGTGAA-39; for GAPDH: for-
ward primer 59-TGACCACAGTCCATGCCATC-39, reverse
primer 59-GACGGACACATTGGGGGTAG-39. Gene expres-
sion was quantitated relative to GAPDH; relative expression of the
target gene was calculated as 2
2DddCt, where dCt is the difference
between the threshold cycle (Ct) for the gene of interest and the Ct
for GAPDH. In each experiment, the value of the relative
expression of the control sample (untreated) was given a value of 1
and the expression of other treatments was plotted relative to the
control. All samples were analyzed in duplicate and repeated at
least three times.
Immunofluorescence Staining for Detection of NF-kB p65
in RAW264.7 Cells
NF-kB p65 translocation into the nucleus, as an index of NF-kB
activation, was measured using Immunofluorescence staining.
Cells were plated on to cover slips to 70% confluence and
preincubated for an hour with 50 mM PAPep and subsequently
incubated with 100 ng/ml LPS for 30 min. Cells were washed in
PBS and fixed with 3.7% paraformaldehyde and permeabilized
with 0.1% Triton X-100. Slides were blocked with 10% goat
serum (Vector Laboratories, Burlingame, CA) for 1 h and
incubated overnight at 4uC with anti-NF-kB p65 antibody
(1:1000, Cell Signaling Technology Inc., Beverly, MA), followed
the next day by a one-hour incubation at room temperature with
anti-rabbit IgG antibody labeled with Alexa Fluor 555 (Molecular
Probes, Eugene, Oregon, USA). Sections were mounted with
Vectashield mounting medium with DAPI (Vector Laboratories,
Burlingame, CA) and visualized and photographed under a
confocal laser scanning microscopy (Zeiss LSM510; Carl Zeiss,
Thornwood, NY). The number of cells with p65 nuclear
translocation in six random fields were counted in a masked
fashion and expressed as a percentage of the number of
translocated cells in comparison to that of total cells. Experiments
were performed in triplicate and repeated at least three times.
Quantification of PAPep Effects on NF-kB Activation in
Ocular Tissue and Different Cell Types
The phosphorylation of NF-kB p65 subunit, particular on serine
residues 536 in the C-terminal transactivation domain, plays an
important role in regulating the expression of various genes
encoding pro-inflammatory cytokines and adhesion molecules. To
further prove that PAPep might play a role in the regulation of
phosphorylation of NF-kB p65
Ser536, Western blot analysis was
performed in both ocular tissues and different cell types.
The retina and ICB complex obtained 3 h after EIU induction
were lysed using the ProteoJET
TM Mammalian Cell Lysis Reagent
from Fermentas under conditions for preparation of protein
extracts. RAW 264.7 cells as model of immune cells, and human
umbilical vein endothelial cells (HUVECs) were preincubated for
an hour with various doses of PAPep (1 mM, 10 mM and 50 mM)
and activated with LPS (100 ng/ml) or TNF-a (10 ng/ml) for 30
minutes. Then, whole cell extracts were obtained. Protein
concentration of the homogenate was determined following
Bradford’s colorimetric method. Each sample containing 50 mg
total protein was separated by SDS-PAGE and electroblotted to
polyvinylidene fluoride membrane (Millipore, Billerica, MA,
USA). After blocking nonspecific binding with 5% BSA, the
membranes were incubated with primary antibodies against
phosphor-NF-kB p65 (Ser536) or NF-kB p65 (all 1:1000, Cell
Signaling Technology Inc., Beverly, MA) at 4uC overnight. After
incubation with horseradish peroxidase-conjugated anti-rabbit
antibody (1:1,000; R&D Systems, Minneapolis, MN, USA) for
2 h at room temperature, proteins were visualized by Immobilon
Western Chemiluminescent HRP Substrate (Millipore, Billerica,
MA, USA). The relative band intensity for phosphor-NF-kB p65
was calculated in comparison to that for NF-kB p65 after
densitometry analysis with computer software, ImagePro Plus
6.0 (Media Cybernetics Inc., Bethesda, MD, USA).
Monocytic Cell–Endothelial Cell Adhesion Assay
The impact of PAPep on adherence of U937 cells to TNF-a-
activated HUVECs was evaluated as described previously [32–
33]. Briefly, HUVECs at a density of 1.0610
5 cells/well were
cultured in 10% FBS ECM on a 24-well plate. When reaching
90%–95% of confluence, the cells were starved in serum free
ECM medium for 12 h, and then exposed to PAPep (1, 10,
50 mM) or PAPS (50 mM) for 18 h, followed by 6 h stimulation
with TNF-a (10 ng/ml). U937 cells freshly harvested were labeled
with CM-H2DCFDA (10 mM) (Invitrogen, Grand Island, NY) in
10% FBS RPMI 1640 medium at 37uC for 30 min. After
extensively washing with PBS, the CM-H2DCFDA -labeled U937
cells were gently added in triplicate into the HUVEC wells that
had been treated with PAPep or PAPS, and then incubated at
37uC for another 30 min. Non-adhered U937 cells were then
gently washed out with 1% FBS PBS and HUVECs were fixed
with 4% paraformaldehyde in PBS for 10 min, followed by
20 min at room temperature with rhodamine phalloidin from
Molecular Probes (Eugene, Oregon, USA). Random fields were
imaged under a confocal laser scanning microscopy (Zeiss
LSM510; Carl Zeiss, Thornwood, NY). The numbers of adhered
U937 cells were counted in a masked fashion and expressed as the
number of adhered cells per field. Experiments were performed in
triplicate and repeated at least three times.
Effects of PAPep on Adhesion Molecule Expression in
Endothelial Cells
HUVECs were incubated for 24 h at 37uC with 5% CO2,
starved overnight, treated with various concentrations of PAPep
A Novel Peptide Inhibits Inflammation
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10 ng/ml TNF-a and harvested 6 h later. Whole cell extracts were
obtained and primary antibodies against ICAM-1 (1:1000;
Epitomics Inc., Burlingame, CA) were used to detect protein
expression of ICAM-1 by Western blot as described above.
GAPDH (1:1000; KangChen Bio-tech, Shanghai, China) was used
as loading control.
Statistical Analysis
Data are expressed as mean 6 SD of at least three independent
experiments. Severity of EIU was analyzed using the nonpara-
metric Mann-Whitney U test. Differences between mean values of
multiple groups were analyzed by one-way analysis of variance
with Dunnett’s test for post hoc comparisons. A P-value less than
0.05 was considered statistically significant. All computations were
performed with the SPSS16.0 (Chicago, IL) software.
Results
Identification of PAPep Peptide as a Potential
Inflammatory Inhibitor from the C-type lectin domain of
PAP
We first analyzed the peptides’ characteristics including
isoelectric point, half-life, net charge at PH 7.0 using ExPASy
(http://www.expasy.ch/tools/protparam.html). As shown in
Table 1, these are all small peptides with molecular mass less
than 2 kDa, half-life between 2.8–100 h. Unlike the other two
peptides, PAPep (P3) is slightly positively charged at neutral pH
(charge +2.0) and has an isoelectric point of 9.99, which means
that under neutral pH environments the peptide retains its positive
charge. This cationic property is believed to be very important for
peptide interactions with negatively charged membranes and/or
cell walls of Gram-negative bacteria [34,35].
Using DNAStar software, we then analyzed the mean
hydrophilicity (Kyte & Dolittle), antigenic index (Jameson-Wolf)
and surface probability (Emini) of these 3 peptides (data not
shown). PAPep (P3) has higher mean hydrophilicity, antigenic
index and surface probability compared with the other two
peptides, suggesting that PAPep possesses better properties of
hydrophilicity, antigenicity, and surface accessibility, which are
essential for it to perform biological functions in vivo.
To identify the key active region in CTLD domain of PAP
protein in anti-inflammation, we examined the potential effects of
the 3 peptides (P1–P3) on ocular inflammation in EIU rats by
grading of clinical score, measurement of protein concentration
and cell infiltration in the AqH. As shown in Figures 2A–2C, little
anti-inflammatory effect was observed with P1 peptide, while P2
and PAPep (P3) can both attenuate the clinical manifestation in
EIU rats compared with vehicle-treated group. However, P2
couldn’t exhibit its anti-inflammatory effect until reaching a
relatively high concentration of 50 mg/eye, and PAPep showed
more significant inhibition effect at concentration as low as 10 mg/
eye, which was 5 times lower than that of P2 (data of dose
responses for P2 are not shown). Based on the results of
bioinformatics analysis and in vivo experiment, we chose to further
study the anti-inflammatory activity of PAPep (P3).
Clinical Scores, Protein Concentration, and Number of
Cells in the Aqueous Humor after Injection of PAPep and
LPS
Then, we further explored the effect of intravitreal injection of
PAPep on ocular inflammation in the anterior segment and
compared its effect with dexamethasone. As shown in Figure 3B,
severe inflammation was found in the anterior chamber 24 h after
LPS administration, and the clinical score for the EIU rats was
3.7560.27. By contrast, PAPep treatment reduced the inflamma-
tion (Fig. 3D) and improved clinical score in a dose dependent
manner (Fig. 3F). By intravitreal injection of 10 mg/eye PAPep,
clinical score was significantly (P,0.01) reduced to 1.5060.45
compared with vehicle-treated group, and the effect was
comparable with that of the positive control group receiving
dexamethasone (1.1760.26) (Fig. 3E and 3F). However, intravit-
real injection of PAPS had no therapeutic effect on ocular
inflammation (mean clinical score: 3.8360.26).
Consistent with the clinical signs, a very low level of soluble
protein (2.3160.83 mg/ml) and no inflammatory cells were found
in the AqH of the control rats. In LPS group, however, the protein
levels and number of inflammatory cells in the AqH were
38.7462.21 mg/ml and 59611610
5 cells/ml, respectively, sig-
nificantly higher than those in the control group (Fig. 4A and 4B).
Relative to vehicle-treated rats, the LPS-induced elevation of
soluble proteins and increase number of inflammatory cells were
dose-dependently and significantly reduced in animals pretreated
intravitreally with PAPep. The calculated reductions over protein
leakage and cellular influx caused by PAPep (10 mg/eye)
pretreatment were 67 and 78%, respectively. Pretreatment with
dexamethasone (10 mg/eye) also significantly reduced the protein
leakage and cellular infiltration into the AqH compared with
vehicle-treated animals (inhibitions of 80 and 87%, respectively).
However, intravitreal pretreatment with PAPS (10 mg/eye) did not
reduce the cellular infiltration (5765610
5 cells/ml) and protein
leakage (39.5761.92 mg/ml) into the AqH.
PAPep Suppressed Histopathological Changes of EIU
Histopathological changes of EIU were evaluated and inflam-
matory cells infiltrating the eye were counted 24 hours after EIU
induction. Histological analysis revealed no infiltrating cells in the
eyes of animals that had received a footpad injection of sterile
saline (control group, Fig. 5A). On the other hand, the histological
evaluation from the LPS-treated rats revealed signs of severe
uveitis with massive neutrophil and monocyte infiltration, mainly
into the ICB (107616 cells/section; Fig. 5B) but also into the
posterior vitreous (4967 cells/section; Fig. 5G). Pretreatment with
PAPep (10 mg/eye) exhibited a significantly milder uveitis and
reduced number of inflammatory cells compared with vehicle-
treated animals (Fig. 5D and 5I). On average, 1162 and 762
inflammatory cells per ocular section were detected in the ICB and
posterior vitreous during EIU, respectively (Fig. 5K and 5I). A
similar inhibition was also found for intravitreal pretreatment with
dexamethasone (10 mg/eye). In PAPS treatment group, 96612
and 5466 inflammatory cells per ocular section were detected in
the ICB and posterior vitreous, which was not significantly
Table 1. The properties of the three newly identified
peptides.
Peptide P1 P2 PAPep(P3)
Number of Amino Acids 16 16 16
Molecular Weight (Da) 1798 1566.8 1915.1
Isoelectric Point 4.21 5.97 9.99
Estimated Half-life (h) 2.8 100 4.4
Net Charge at PH 7.0 -1 0 2
doi:10.1371/journal.pone.0029155.t001
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there was no sign of cytotoxicity in any of the treatment groups.
Eye structures exhibited no histologic alteration other than some
preparation artifacts.
PAPep Decreased LPS-induced TNF-a and IL-6 Expression
in AqH during EIU
Cytokines such as TNF-a and IL-6 are important molecules in
inflammatory processes and induced by various factors, including
bacterial endotoxin LPS [36]. We investigated whether PAPep
suppressed LPS-induced TNF-a and IL-6 release in EIU rats. In
saline-treated animals (control group), undetectable or very low
levels of TNF-a and IL-6 were found in the AqH. As expected, up-
regulated levels of TNF-a and IL-6 were present in rat AqH 24 h
after LPS stimulation. When administered intravitreally, PAPep
(5 mg/eye and 10 mg/eye) significantly reduced the augmentation
of both inflammatory cytokines in response to LPS (Fig. 6A and
6B). Especially with 10 mg/eye of PAPep, the inhibitions obtained
in the levels of TNF-a and IL-6 were 79 and 75%, respectively. A
similar effect was verified in the group pretreated intravitreally
with dexamethasone (inhibitions of 88 and 89% for TNF-a and
IL-6, respectively). Meanwhile, no effect was verified in the group
pretreated intravitreally with 10 mg/eye of PAPS.
PAPep Reduced Retinal and ICB Expression of ICAM-1
and MCP-1 during EIU
To investigate molecular mechanisms underlying retinal
leukocyte recruitment and adhesion, protein levels of ICAM-1
(Figs. 7A) and MCP-1 (Figs. 7B) in the retina and ICB complex
were evaluated by ELISA. Retinal ICAM-1 and MCP-1 protein
Figure 2. Anti-inflammatory effects of PAP peptides (P1–P3) in EIU rats. The rats were treated with PAP peptides (P1–P3) in different
concentrations 1 h before LPS (200 mg) injection, and were evaluated 24 h after LPS challenge. Clinical scores (A) were graded in a blinded fashion.
Protein levels (B) and cell count (C) were assessed in the AqH 24 h after EIU. Data are expressed as mean6SD (n=8 per group). ##,P ,0.01
compared with control group; *, P,0.05 or **, P,0.01 compared with vehicle-treated group; 1,P ,0.01 compared with P2-treated group.
doi:10.1371/journal.pone.0029155.g002
Figure 3. The effects of PAPep on clinical development of EIU. The rats were treated with vehicle (PBS), PAPS (10 mg/eye), PAPep (1, 5, 10 mg/
eye) or dexamethasone (10 mg/eye) 1 h before LPS (200 mg) injection, and were evaluated 24 h after LPS challenge with biomicroscope examination.
Clinical manifestation of EIU in Wistar rats are shown in Figure A–E. Rats of control group (A) showed no inflammation in the anterior chamber. Severe
inflammation was observed in vehicle-treated rats (B) and rats treated with PAPS (C). Note the fibrinous pupillary membrane (arrow). In the group of
EIU rats treated with PAPep (10 mg/eye; D), attenuation of inflammation was observed compared with vehicle-treated rats. A similar inhibition was
also found for intravitreal pretreatment with dexamethasone (E). (F) Effect of various dosages of PAPep on clinical scores in EIU rats, which were
graded in a blinded fashion 24 h after EIU. Data are expressed as mean6SD (n=8 per group). ##,P ,0.01 compared with control group; *, P,0.05 or
**, P,0.01 compared with vehicle-treated group. Dex, dexamethasone.
doi:10.1371/journal.pone.0029155.g003
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EIU rats than in saline-treated controls. Intravitral injection of
PAPep (10 mg/eye) significantly (P,0.01 for both) reduced ICAM-
1 and MCP-1 protein levels by 61 and 60%. Intravitreal treatment
with dexamethasone (10 mg/eye) also significantly reduced the
expression of ICAM-1 and MCP-1 during EIU. No inhibition
effect was found for intravitreal pretreatment with PAPS (10 mg/
eye).
Toxicity Evaluation of Intravitreal Administration of
PAPep
Five normal rats received intravitreal injection of PAPep(10 mg/
eye) were used to detect proinflammatory effect of the peptide and
determine the short-term safety of the treatment. No inflammatory
sign in the anterior chamber was detected in any eye in normal
rats receiving intravitreal injection of PAPep. Cataract and
vitreous opacity was not observed during the observation period
(3 days). Histopathologic analysis did not show any evidence of
drug-released toxic effect in the PAPep injection group.
PAPep Inhibited the mRNA Levels of TNF-a and IL-6 and
the Translocation of NF-kB in RAW264.7 Cells
To further confirm these observations in EIU rats, we
investigated the effects of PAPep on the activation of macro-
phage-like cells, which plays a key role in the orchestration of the
inflammatory response during acute uveitis. Activation in vitro of
RAW264.7 cells by LPS (100 ng/ml) was monitored by measuring
the expression of TNF-a and IL-6 mRNAs, GAPDH mRNA
being used as control. Resting RAW264.7 cells showed a low
constitutive transcription of pro-inflammatory cytokines, while
LPS caused a significant increase in mRNA levels of TNF-a and
IL-6 in RAW264.7 cells after 6 h of incubation. Adding PAPep to
the culture medium inhibited that induction in a dose-dependent
manner, the minimum concentration having a significant effect
being 1 mM (Fig. 8A and 8B). However, no inhibitory effect was
verified in cells pretreated with PAPS (50 mM). Dexamethasone
(10 mM) also significantly inhibited LPS-induced mRNA expres-
sions of TNF-a and IL-6. Importantly, PAPep (50 mM) and Dex
(10 mM) had a similar inhibitory effect on LPS-induced mRNA
levels of IL-6 (P.0.05). These results suggest that the PAPep
prevented TNF-a and IL-6 production through suppressing their
gene expressions in LPS-stimulated RAW264.7 cells. Moreover, in
an immunofluorescence method, we found that 100 ng/ml LPS
caused the nuclear translocation of the p65 subunit of NF-kB, and
pretreatment with 50 mM PAPep significantly inhibited the LPS-
evoked NF-kB nuclear translocation (Fig. 9). These results suggest
that RAW264.7 cells’ activation is mediated by the translocation
of NF-kB to the nucleus and PAPep exerts anti-inflammatory
effects probably through the inhibition of NF-kB translocation.
PAPep Inhibited Phosphorylation of NF-kB p65 in Ocular
Tissues and Different Cell Types
The presence of activated NF-kB in the nucleus was further
confirmed by Western blot. We measured the phosphorylated p65
NF-kB protein level both in ocular tissues and different cell lines,
RAW264.7 cells and HUVECs. Under homeostatic conditions,
low levels of phosphorylated p65 NF-kB was found in the ICB and
retina complex. EIU, as expected, induced marked phosphoryla-
tion of p65 NF-kB in the cells of ICB and retina. Intravitreal
PAPep pretreatment significantly reduced the activation of p65
NF-kB in the ICB and retina complex compared with the vehicle-
treated group (Fig. 10A). The inhibition in the p65 NF-kB
phosphorylation by PAPep (10 mg/eye) was 70.3%, while total p65
NF-kB remained unchanged.
Likewise, no expression of the phosphorated p65 NF-kB protein
was detected in unstimulated RAW264.7 cells and HUVECs, but
there was strong expression in LPS-stimulated RAW264.7 cells
and TNF-a-stimulated HUVECs (Fig. 10B and 10C). Expression
of phophorated p65 NF-kB protein decreased in the 10 to 50 mM
PAPep group in a dose-dependent fashion in both RAW264.7 cells
and HUVECs. These results indicated the potential role of NF-kB
in the suppression of inflammatory mediators and pro-inflamma-
tory cytokines by PAPep.
Figure 4. The effects of PAPep on protein leakage and cellular infiltration into the aqueous humor during EIU. The rats were treated
with vehicle (PBS), PAPS (10 mg/eye), PAPep (1, 5, 10 mg/eye) or dexamethasone (10 mg/eye) 1 h before LPS (200 mg) injection. Protein levels (A) and
cell count (B) were assessed in the AqH 24 h after EIU. Data are expressed as mean6SD (n=8 per group). ##,P ,0.01 compared with control group;
**, P,0.01 compared with vehicle-treated group. Dex, dexamethasone.
doi:10.1371/journal.pone.0029155.g004
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stimulated HUVECs
Macrophages are not the only cells that can generate
proinflammatory factors during the early stages of uveitis.
Endothelial cells also release chemokines such as ICAM-1 through
NF-kB activation [33,37]. We therefore investigated the effect of
PAPep on the adhesion of U937 cells to TNF-a-activated
endothelial cells, a critical step in vascular inflammation. As
shown in Figure 11A, control-confluent HUVECs showed
minimal binding of U937 cells, while stimulation of HUVECs
with TNF-a for 6 h resulted in a 15-fold increase in firmly
adhering U937 cells as compared with resting HUVECs.
Figure 5. Histological evaluation of EIU rats treated with PAPep. The rats were treated with vehicle (PBS), PAPS (10 mg/eye), PAPep (10 mg/
eye) or dexamethasone (10 mg/eye) 1 h before LPS (200 mg) injection. Rats’ eyes were enucleated 24 h after LPS stimulation, fixed, sectioned, and
stained with H&E. Photographs on the left side show ICB region and those on the right side show posterior vitreous and retina in rat. Rats of control
group (A, F) showed no infiltrating cells in the eye. Severe inflammatory cell infiltration was observed in vehicle-treated rats (B, G) and rats treated
with PAPS (10 mg/eye; C, H). In the group of EIU rats treated with PAPep (10 mg/eye; D, I), milder uveitis and reduction of cell infiltration were
observed compared with EIU rats. A similar inhibition was also found for intravitreal pretreatment with dexamethasone (10 mg/eye; E, J). Arrows:
inflammatory cells. Original magnification (A-J)6100; (insets: A-J)6400. (K-L) Number of inflammatory cells infiltrating the eye during EIU.
Inflammatory cells in the ICB (K) and posterior vitreous (L) were counted 24 hours after EIU induction. Results are representative of those in six pairso f
eyes. Data are expressed as mean6SD (n=5 per group). ##,P ,0.01 compared with control group; **, P,0.01 compared with vehicle-treated group.
Dex, dexamethasone; N.D., Not detected.
doi:10.1371/journal.pone.0029155.g005
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HUVECs was significantly attenuated by PAPep in a dose
dependent manner (Fig. 11E). PAPS didn’t show any effect on
U937 cells adhesion to HUVECs (Fig. 11C).
U937 Cells Adhesion to HUVECs Is ICAM-1-dependent
As the expression of adhesion molecules on endothelial cells is a
prerequisite for adhesion of leukocytes and monocytes, we
investigated the effect of PAPep on TNF-a-induced ICAM-1
expression in HUVECs. Western blot analysis of cell lysates
showed that levels of ICAM-1 were undetectable in unstimulated
HUVECs, but were significantly increased by TNF-a treatment.
PAPep significantly attenuated TNF-a-induced ICAM-1 upregu-
lation in a dose-dependent manner at concentrations ranging from
10 to 50 mM (Figure 12). However, no inhibitory effect was
observed by pretreatment with PAPS. Since PAPep similarly
interfered with TNF-a-induced up-regulation of NF-kB expression
by HUVECs, we supposed that PAPep suppresses U937 cells
adhesion to HUVECs via NF-kB signaling.
PAPEP Is Non-toxic to RAW 264.7 Cells and HUVECs
The results in the cytotoxicity MTS study showed that after
24 h incubation with PAPep, there was no variation in cell
viability at concentrations tested (1–100 mM, data not shown).
Figure 6. Effects of PAPep on cytokine production in the AqH during EIU. Vehicle (PBS), PAPS (10 mg/eye), PAPep (1, 5, 10 mg/eye) or
dexamethasone (10 mg/eye) was applied intravetreally to both rat eyes 1 h before LPS (200 mg) administration. TNF-a (A) and IL-6 (B) levels were
assessed in the AqH 24 h after EIU. Data are expressed as mean6SD (n=8 per group). ##,P ,0.01 compared with control group; **, P,0.01
compared with vehicle-treated group. Dex, dexamethasone; N.D., Not detected.
doi:10.1371/journal.pone.0029155.g006
Figure 7. Effects of PAPep on ICAM-1 and MCP-1 expression in the ICB and retina complex during EIU. Vehicle (PBS), PAPS (10 mg/eye),
PAPep (1, 5, 10 mg/eye) or dexamethasone (10 mg/eye) was applied intravetreally to both eyes 1 h before LPS (200 mg) administration. Protein levels
of ICAM-1 (A) and MCP-1 (B) were assessed in the retina and ICB complex 24 h after EIU. Data are expressed as mean6SD (n=8 per group). ##,
P,0.01 compared with control group; **, P,0.01 compared with vehicle-treated group. Dex, dexamethasone; N.D., Not detected.
doi:10.1371/journal.pone.0029155.g007
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but no significant differences were observed. No effects on cell
viability were observed in cells treated with PAPS (50 mM).
Discussion
PAP is a 175-amino-acid-long polypeptide containing a large C-
type lectin carbohydrate recognition domain linked to a short N-
terminal domain. Although there are increasing number of studies
showing that the CTLD are involved in regulatory processes
pertaining to various aspects of the immune system, such as
inflammation [12–23], immunity to tumor [38,39] and virally
infected cells [40], it is unclear which fragment of CTLD is the key
active region and the underlying mechanism of its anti-
inflammation. In this study, we first preliminarily investigate the
whole domain by sequence alignment, second structure analysis
and bioinformatics analysis to theoretically screen out the most
promising regions that might within the key active region of
human PAP. Then we examined the potential effects of the
selected three peptides on ocular inflammation in EIU rats to
ultimately identify which peptide is most likely to possess anti-
inflammatory effect. Finally, we showed for the first time a 16-
amino acid peptide (PAPep) derived from CTLD of PAP with
potent anti-inflammatory activity using both in vivo and in vitro
assays. We demonstrated that intravitreal injection of PAPep
effectively attenuates the clinical manifestation in EIU rats,
diminishes the cellular infiltration, protein leakage into the
anterior chamber, reduces pro-inflammatory cytokines and
molecules production, and improves histopathologic manifestation
of EIU, while other two synthesized peptides and scrambled
peptide had no such effects. Furthermore, PAPep suppresses the
LPS-induced mRNA expression of TNF-a and IL-6 in RAW
264.7 cells, and inhibits adhesion molecule expression in
stimulated endothelial cells, and these anti-inflammatory effects
are probably associated with the inhibition of NF-kB activation.
Hence, the amino acid sequence of PAPep studied might be a part
of the critically active sequence of PAP CTLD in anti-
inflammation and its function is sequence-dependent.
EIU is an experimental model for acute ocular inflammation,
produced by footpad injection of endotoxin, the lipopolysaccha-
ride (LPS) component of gram-negative bacterial cell wall [41,42].
In the ocular tissue, exposure to LPS is known to induce the
breakdown of the blood–aqueous barrier, which leads to protein
transudate in the anterior chamber, infiltration of macrophages
and neutrophils into the eye, and production of multiple
proinflammatory mediators, including cytokines and chemokines,
such as TNF-a, IL-6, MCP-1 and ICAM-1 [36,41,43,44]. The
overproduction of these cytokines is mediated through NF-kB
[45,46]. These clinical, biochemical, immunological and histolog-
ical characteristics make EIU a suitable in vivo model to evaluate
the therapeutic efficacy of drugs for the treatment of inflammatory
ocular diseases in humans.
The first report suggesting an anti-inflammatory effect of PAP,
the protein that peptide was derived from, was based on an ex vivo
model of isolated lung. In that model, PAP administration reduced
the edema and synthesis of thromboxane A2 induced by fMLP
[18]. There are also researchers proving that PAP could block
inflammatory responses induced by TNF-a in different cell lines
[19,20,22]). In the present study, we showed for the first time that
PAPep, which was derived from PAP protein, exerted anti-
inflammatory effects in ocular inflammation induced by LPS, a
TLR4 agonist. We demonstrated that intravitreal injection of
PAPep could significantly reduce EIU clinical scores, decrease the
number of infiltrating inflammatory cells and the protein leakage
into the anterior chamber, and suppress histopathologic changes of
EIU. Moreover, the intravetreal administration of PAPep also
significantly diminished TNF-a and IL-6 production in the AqH
of the eye during EIU, and suppressed the LPS-induced mRNA
expression of TNF-a and IL-6 in RAW 264.7 cell as well. These
results are in accordance with previous work by Vasseur et al.[20]
who reported that in rat macrophages in vitro, PAP could almost
completely prevent the induction of TNF-a and IL-6 mRNA
expression. However, whether the peptide has anti-inflammatory
effect on other TLR agonists remains unknown and need further
studies.
Figure 8. PAPep inhibited LPS-induced TNF-a and IL-6 mRNA expression in RAW264.7 cells. RAW264.7 cells were pretreated with PAPep
(1, 10, 50 mM), PAPS (50 mM), or dexamethasone (10 mM) for 1 h, and then stimulated with LPS (100 ng/ml) for 6 h. TNF-a (A) and IL-6 (B) mRNA
induction levels were quantified by real-time PCR and normalized to GAPDH mRNA expression. All samples were analyzed in duplicate and repeated
at least three times. Data are expressed as mean6SD. ##,P ,0.01 compared with control group; *, P,0.05 or **, P,0.01 compared with LPS group.
Dex, dexamethasone.
doi:10.1371/journal.pone.0029155.g008
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e29155Figure 9. Effect of PAPep on nuclear translocation of NF-kB in RAW264.7 cells. (A) The intracellular location of NF-kB p65 was determined
in RAW264.7 cells by immunofluorescence using an anti-NF-kB p65 antibody with Alexa Fluor 555 labelling (red fluorescence), and the nuclei were
counterstained with DAPI (blue fluorescence). (a) Untreated cells exhibit the localization of NF-kB in the cytoplasm. Cells stimulated with 100 ng/ml
LPS (b) and 50 mM PAPS(c) display a significant increase in the translocation of NF-kB into the nucleus. (d) Stimulated cells in the presence of 50 mM
PAPep maintained predominantly cytoplasmic NF-kB immunostaining, indicating inhibition of NF-kB translocation. Results are displayed individually
or as merged images (confocal fluorescence microscopy). Data represent one of three experiments with similar results. Scale bars, 10 mm. (B) Nuclear
NF-kB was quantitated by visual fluorescent microscopy. The number of cells with p65 nuclear translocation in six random fields were counted in a
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inflamed ocular tissues such as the iris [47], vitreous cavity [48,49],
and retina [50] in the EIU model, with neutrophils and
macrophages being major leukocyte constituents. MCP-1 is known
as one of the important determinants of leucocyte recruitment,
and is up-regulated during EIU [44,51,52]. Our study demon-
strated that PAPep could directly affect the expression of MCP-1
in ocular tissues in a dose-dependent manner, thus counteracting
the inflammatory response by inhibiting leukocyte recruitment
into the eye. These results were consistent with what we showed in
histopathology study that LPS-induced acute inflammation caused
the increase of leukocyte recruitment into the eye, while PAPep
treatment significantly reduced the infiltrated leukocytes into the
ICB and posterior vitreous cavity.
Increased expression of adhesion molecules is another impor-
tant factor involved in the pathogenesis of EIU [48,51], and
ICAM-1 is known to be a key molecule in which its reduction
results in attenuation of leukocyte adhesion and/or transmigration
[49,53,54]. Previous reports demonstrated that PAP significantly
inhibited TNF-a induced adhesion molecule upregulation in
HUVECs in a dose dependent manner [19]. In our study, we
found that PAPep significantly decreased the protein levels of
ICAM-1 in the inflamed ICB and retina complexes. Moreover, it
effectively blocked ICAM-1 expression in TNF-a–stimulated
HUVECs by Western blot and inhibited the binding of U937
cells to TNF-a–stimulated HUVECs. These data suggested that
PAPep is involved in the regulation of adhesion molecule
expression and counteracts the inflammatory response by
inhibiting leucocyte recruitment and adhesion in the ocular tissue
as well as vascular endothelium, which was agreed with the
previous studies.
NF-kB is one of the most ubiquitous transcription factors that
regulate gene expressions involved in cellular proliferation,
inflammatory responses, and cell adhesion [55,56]. Upon
stimulation with a wide variety of stimuli including LPS and
TNF-a, NF-kB translocates from the cytoplasm to the nucleus and
plays important roles in sustained inflammatory responses. Li et al.
[57] demonstrated a significant upregulation of activated NF-kB in
the iris-ciliary body (ICB) during EIU. Previous studies have
reported that the anti-inflammatory effects of PAP are mediated
through the inhibition of the NF-kB pathway [20–23]. Our data
also indicate that intravetreal PAPep treatment prevents LPS-
induced NF-kB translocation/activation in the ICB and retina
tissue in EIU rats and in LPS-stimulated RAW264.7 cells as well.
In addition, PAPep also inhibited the TNF-a-evoked activation of
NF-kB in HUVECs. These results indicate that PAPep exerted
anti-inflammatory effect probably associated with the inhibition of
NF-kB activation, and resulted in reduction of ocular inflamma-
tory responses.
In order to observed its safety during injection into the vitreous
cavity. The intraocular tolerance of PAPep was tested in normal
rats. No inflammation or adverse reaction such as cataract or
vitreous opacity was observed in the injected eyes during
evaluation by slit-lamp biomicroscopy, suggesting that PAPep is
well tolerated in the eye in the short term. We thus preliminarily
confirmed the short-term safety of PAPep when administrated
intravitreally. However, long-term side effects of the peptide need
to be evaluated by multiple injections of the peptide with longer
masked fashion and expressed as a percentage of the number of translocated cells in comparison to that of total cells. ##,P ,0.01 compared with
control group, **, P,0.01 compared with LPS group.
doi:10.1371/journal.pone.0029155.g009
Figure 10. Western blot analysis of protein levels of NF-kB p65. (A) The total and phosphorylation levels of NF-kB p65 was analyzed by
Western blot in ICB and retina complex of EIU rats for indicated periods. Lane 1: control; lane 2: LPS and vehicle; lane 3: LPS and PAPS (10 mg/eye);
lane 4: LPS and PAPep (10 mg/eye). (B) RAW264.7 cells were pretreated with PAPep (1, 10, 50 mM) or PAPS (50 mM) for 1 h, then stimulated with LPS
(100 ng/ml) for 30 min. Total and phosphorylation levels of NF-kB p65 was analyzed by Western blot. Lane 1: control; lane 2: LPS; lane 3: LPS and
50 mM PAPS; lane 4: LPS and 1 mM PAPep; lane 5: LPS and 10 mM PAPep; lane 6: LPS and 50 mM PAPep. (C) HUVEC were incubated with PAPep (1, 10,
50 mM) or PAPS (50 mM) for 1 h, then stimulated with TNF-a (10 ng/ml) for 30 min. Total and phosphorylation levels of NF-kB p65 was analyzed by
Western blot. Lane 1: control; lane 2: TNF-a; lane 3: TNF-a and 50 mM PAPS; lane 4: TNF-a and 1 mM PAPep; lane 5: TNF-a and 10 mM PAPep; lane 6:
TNF-a and 50 mM PAPep. ##,P ,0.01 compared with control group, **, P,0.01 compared with LPS or TNF-a group. Data are expressed as mean6SD
of three independent experiments, each performed in duplicates.
doi:10.1371/journal.pone.0029155.g010
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also be performed before any clinical application.
Endotoxin-induced uveitis develops within 24 h of endotoxin
challenge, with spontaneous regression within 48 h [41]. Accord-
ingly, we observed the efficacy of PAPep only up to 24 hours after
injection, which is relatively short time frame of observation.
Hence, long-term study is necessary to determine treatment
efficacy of PAPep in chronic uveitis in the future.
A key finding in this study is that PAPep is a newly discovered
peptide derived from human PAP. Although its anti-inflammatory
activity is not as strong as that of corticosteroids, it has significant
merits compared to conventional proteins and large synthetic
molecules as discussed above, which make it good candidate for
ocular application. However, there are still disadvantages of small
peptides as drugs, one of them being short half-life in vivo. Since
the predicted half-life of PAPep is only 4.4 hrs, frequent and
repeated dosing would be inevitably required for treatment.
Therefore, future studies should focus on overcoming these
disadvantages by chemical modification or conjugation to a
macromolecule to increase its half-life [58–59]. Measures could
also be taken to improve its delivery system with safer and non-
invasive route, such as intravitreous drug delivery system in a
biodegradable polymer [60–61], to maintain a constant concen-
tration of peptide in the vitreous cavity for an extended period of
time to avoid repeated intravitreal injections. Moreover, topical
treatment such as eye drops or ointment is another option under
the condition that the peptide has the capability of penetrating
cornea and anterior chamber, which will also be evaluated in
future studies. These efforts might help to promote the
development of novel peptide drugs and their clinical applications.
In conclusion, our results suggest that intravitreal injection of
PAPep, a newly identified peptide derived from PAP, can
Figure 11. PAPep inhibited U937 cells adhesion to TNF-a-activated HUVEC. (A) HUVEC were incubated with PAPep(1, 10, 50 mM) or
PAPS(50 mM) for 18 h, then stimulated with TNF-a (10 ng/ml) for 6 h. CM-H2DCFDA-labeled (green fluorescence) U937 cells were seed onto HUVEC
and co-cultured for 30 min. After removing the non-adherent cells, adherent cells were fixed and stained with rhodamine phalloidin (red
fluorescence), and were counted under a confocal laser scanning microscopy with magnification of 2006. Results are displayed individually or as
merged images. Data represent one of three experiments with similar results. Scale bars, 10 mm. (B) Quantitative analysis of the binding of U937 cells
to HUVEC presented by bar graphs. ##,P ,0.01 compared with unstimulated cells, **, P,0.01 compared with TNF-a-stimulated cells. Data are
expressed as mean6SD of results from three independent experiments, each performed in duplicate.
doi:10.1371/journal.pone.0029155.g011
Figure 12. Western blot analysis demonstrating the expression of ICAM-1 protein in HUVECs. HUVEC were incubated with PAPep (1, 10,
50 mM) or PAPS (50 mM) for 1 h, then stimulated with TNF-a (10 ng/ml) for another 6 h. Protein levels of ICAM-1 was analyzed by Western blot.
GAPDH was used as loading control. Lane 1: control; lane 2: TNF-a; lane 3: TNF-a and 50 mM PAPS; lane 4: TNF-a and 1 mM PAPep; lane 5: TNF-a and
10 mM PAPep, and lane 6: TNF-a and 50 mM PAPep. ##,P ,0.01 compared with unstimulated cells, **, P,0.01 compared with TNF-a-stimulated cells.
Data are expressed as mean6SD of results from three independent experiments, each performed in duplicate.
doi:10.1371/journal.pone.0029155.g012
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dampen the inflammatory damage by affecting diverse compo-
nents of the inflammatory response, including cytokine production
and adhesion molecule expression. The possible mechanism for
this effect of PAPep may depend on its ability to inhibit the
activation of NF-kB. The exact mechanism through which PAPep
exerts its anti-inflammatory effect is under active investigation.
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